Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20,788,527
-
Total 13F shares
-
170,724,836
-
Share change
-
+3,628,599
-
Total reported value
-
$119,779,564
-
Put/Call ratio
-
1.7%
-
Price per share
-
$0.70
-
Number of holders
-
183
-
Value change
-
-$6,894,879
-
Number of buys
-
70
-
Number of sells
-
103
Institutional Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q1 2023
As of 31 Mar 2023,
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) was held by
183 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
170,724,836 shares.
The largest 10 holders included
Invesco Ltd., BlackRock Inc., VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, STATE STREET CORP, PICTET ASSET MANAGEMENT SA, GEODE CAPITAL MANAGEMENT, LLC, D. E. Shaw & Co., Inc., RENAISSANCE TECHNOLOGIES LLC, and CITADEL ADVISORS LLC.
This page lists
184
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.